David Malcom Rodman - Nov 13, 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role: Chief Medical Officer
Signature: /s/ Adam Levy, Attorney-in-fact
Stock symbol: MLYS
Transactions as of: Nov 13, 2023
Transactions value $: $2,709
Form type: 4
Date filed: 11/14/2023, 06:18 PM
Previous filing: Nov 7, 2023
Next filing: Dec 12, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MLYS	Common Stock	Options Exercise	$2.71K	+5.02K	+50%	$0.54^*	15.1K	Nov 13, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MLYS	Stock Option	Options Exercise	$0	-5.02K	-6.67%	$0.00	70.2K	Nov 13, 2023	Common Stock	5.02K	$0.54	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F2	The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.